Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients

References

• World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (Dec 2023).
   Google Scholar
• Kolansky DM. Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden. Am. J. Manag. Care 15(Suppl. 2), S36–S41 (2009).
   PubMedGoogle Scholar
• Poudel I, Tejpal C, Rashid H, Jahan N. Major adverse cardiovascular events: an inevitable outcome of ST-elevation myocardial infarction? a literature review. Cureus 11(7), e5280 (2019).
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39(2), 119–177 (2017).
   Web of Science ®Google Scholar
• Del Buono MG, Garmendia CM, Seropian IM et al. Heart failure after ST-elevation myocardial infarction: beyond left ventricular adverse remodeling. Curr. Probl. Cardiol. 48(8), 101215 (2023).
   PubMed Web of Science ®Google Scholar
• Daiber A, Chlopicki S. Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: evidence for redox-based therapies. Free Radic. Biol. Med. 157, 15–37 (2020).
   PubMed Web of Science ®Google Scholar
• Yoshii T, Matsuzawa Y, Kato S et al. Endothelial dysfunction predicts bleeding and cardiovascular death in acute coronary syndrome. Int. J. Cardiol. 376, 11–17 (2023).
   PubMed Web of Science ®Google Scholar
• Bravo Baptista S, Faustino M, Brizida L et al. Early peripheral endothelial dysfunction predicts myocardial infarct extension and microvascular obstruction in patients with ST-elevation myocardial infarction. Rev. Port. Cardiol. 36(10), 731–742 (2017).
   PubMedGoogle Scholar
• Fichtlscherer S, Breuer S, Zeiher AM. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the “vulnerable” patient. Circulation 110(14), 1926–1932 (2004).
   PubMed Web of Science ®Google Scholar
• Daiber A, Steven S, Weber A et al. Targeting vascular (endothelial) dysfunction. Br. J. Pharmacol. 174(12), 1591–1619 (2017).
   PubMed Web of Science ®Google Scholar
• Feng Y, Shen C, Ma G et al. Prolonged pain to hospital time is associated with increased plasma advanced oxidation protein products and poor prognosis in patients with percutaneous coronary intervention for ST-elevation myocardial infarction. Heart Vessels 25(5), 374–378 (2010).
   PubMed Web of Science ®Google Scholar
• Gentek R, Hoeffel G. The innate immune response in myocardial infarction, repair, and regeneration. Adv. Exp. Med. Biol. 1003, 251–272 (2017).
   PubMed Web of Science ®Google Scholar
• Panahi M, Papanikolaou A, Torabi A et al. Immunomodulatory interventions in myocardial infarction and heart failure: a systematic review of clinical trials and meta-analysis of IL-1 inhibition. Cardiovasc. Res. 114(11), 1445–1461 (2018).
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang H, Liang B, Sun L, Bai L. Prognostic implication of systemic inflammatory state on antiplatelet effect in patients after percutaneous coronary intervention for ST-elevation myocardial infarction: a retrospective cohort study. Medicine (Baltimore) 100(37), e27214 (2021).
   PubMed Web of Science ®Google Scholar
• Fonseca FA, Izar MC. Role of inflammation in cardiac remodeling after acute myocardial infarction. Front. Physiol. 13, 927163 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang M, Xu YJ, Mengi SA, Arneja AS, Dhalla NS. Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp. Clin. Cardiol. 9(2), 103–111 (2004).
   PubMedGoogle Scholar
• Mccarty MF, O'keefe JH, Dinicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open heart 3(1), e000365 (2016).
   PubMed Web of Science ®Google Scholar
• Broderick C, Forster R, Abdel-Hadi M, Salhiyyah K. Pentoxifylline for intermittent claudication. Cochrane Database Syst. Rev. 10(10), CD005262 (2020).
   PubMedGoogle Scholar
• Food and Drug Administration. Trental (Pentoxifylline). https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018631s040lbl.pdf
   Google Scholar
• Ueno M, Ferreiro JL, Tomasello SD et al. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. JACC Cardiovasc. Interv. 4(8), 905–912 (2011).
   PubMed Web of Science ®Google Scholar
• Fernandes JL, De Oliveira RTD, Mamoni RL et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease – a randomized placebo-controlled study. Atherosclerosis 196(1), 434–442 (2008).
   PubMed Web of Science ®Google Scholar
• Brie DM, Mornos C, Brie DA, Luca CT, Petrescu L, Boruga M. Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome. Exp. Ther. Med. 23(6), 378 (2022).
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 (2010).
   PubMed Web of Science ®Google Scholar
• Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20), 2191–2194 (2013).
   PubMed Web of Science ®Google Scholar
• Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual. Assur. 6(2), 65–74 (1998).
   PubMedGoogle Scholar
• Ibanez B, James S, Agewall S et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39(2), 119–177 (2018).
   PubMed Web of Science ®Google Scholar
• Mocan M, Mocan Hognogi LD, Anton FP et al. Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction. Dis. Markers 2019, 7583690 (2019).
   PubMed Web of Science ®Google Scholar
• Andreassen AK, Nordøy I, Simonsen S et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am. J. Cardiol. 81(5), 604–608 (1998).
   PubMed Web of Science ®Google Scholar
• Tubaro M. ESC 2017 STEMI Guidelines: a step forward for a better cure. Eur. Heart J. Cardiovasc. Pharmacother. 4(3), 133–135 (2018).
   PubMed Web of Science ®Google Scholar
• Mohammadpour AH, Falsoleiman H, Shamsara J, Allah Abadi G, Rasooli R, Ramezani M. Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients. Iran Biomed. J. 18(1), 23–27 (2014).
   PubMedGoogle Scholar
• Yu J, Liu Y, Peng W, Xu Z. Serum VCAM-1 and ICAM-1 measurement assists for MACE risk estimation in ST-segment elevation myocardial infarction patients. J. Clin. Lab. Anal. 36(10), e24685 (2022).
   PubMed Web of Science ®Google Scholar
• Postadzhiyan AS, Tzontcheva AV, Kehayov I, Finkov B. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and their association with clinical outcome, troponin T and C-reactive protein in patients with acute coronary syndromes. Clin. Biochem. 41(3), 126–133 (2008).
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Ballantyne CM, Sharrett AR et al. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96(12), 4219–4225 (1997).
   PubMed Web of Science ®Google Scholar
• Richter V, Rassoul F, Purschwitz K, Hentschel B, Reuter W, Kuntze T. Circulating vascular cell adhesion molecules VCAM-1, ICAM-1 and E-selectin in dependence on aging. Gerontology 49(5), 293–300 (2003).
   PubMed Web of Science ®Google Scholar
• Zou Y, Jung KJ, Kim JW, Yu BP, Chung HY. Alteration of soluble adhesion molecules during aging and their modulation by calorie restriction. FASEB J. 18(2), 320–322 (2004).
   PubMed Web of Science ®Google Scholar
• Bilsborough W, O'driscoll G, Stanton K et al. Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in Type II diabetes. Clin. Sci. (Lond.) 103(2), 163–169 (2002).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Mi D, Dubé MP et al. Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial. PLOS ONE 8(4), e60852 (2013).
   PubMed Web of Science ®Google Scholar
• Gupta SK, Dubé MP, Stein JH, Clauss MA, Liu Z. A pilot trial of pentoxifylline on endothelial function and inflammation in HIV-infected patients initiating antiretroviral therapy. AIDS 30(13), 2139–2142 (2016).
   PubMed Web of Science ®Google Scholar
• Hayek A, Paccalet A, Mechtouff L et al. Kinetics and prognostic value of soluble VCAM-1 in ST-segment elevation myocardial infarction patients. Immun. Inflamm. Dis. 9(2), 493–501 (2021).
   PubMed Web of Science ®Google Scholar
• Troncoso MF, Ortiz-Quintero J, Garrido-Moreno V et al. VCAM-1 as a predictor biomarker in cardiovascular disease. Biochim. Biophys. Acta Mol. Basis Dis. 1867(9), 166170 (2021).
   PubMed Web of Science ®Google Scholar
• Brie D, Sahebkar A, Penson PE et al. Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials. J. Hypertens. 34(12), 2318–2329 (2016).
   PubMed Web of Science ®Google Scholar
• Maiti R, Agrawal NK, Dash D, Pandey BL. Effect of pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive Type 2 diabetes mellitus patients. Vasc. Pharmacol. 47(2–3), 118–124 (2007).
   PubMed Web of Science ®Google Scholar
• Keskin E, Oztekin Menevse E, Col R, Sivrikaya A, Uney K, Yazar E. Effect of pentoxifylline on antioxidant status of healthy and endotoxemic New Zealand White Rabbits. Acta Veterinaria Brno 74(1), 17–21 (2005).
   Web of Science ®Google Scholar
• Le Campion ER, Jukemura J, Coelho AM, Patzina R, Carneiro D'albuquerque LA. Effects of intravenous administration of pentoxifylline in pancreatic ischaemia-reperfusion injury. HPB (Oxford) 15(8), 588–594 (2013).
   PubMed Web of Science ®Google Scholar
• Al-Saedi HF, Hussein UaR, Ramadhan MA. Protective effects of pentoxifylline against adriamycin-induced cardiotoxicity in rabbits. J. Pharmaceut. Negative Res. 13(2), 51–56 (2022).
   Google Scholar
• Motawi TK, Darwish HA, Abd El Tawab AM. The relative efficacy of aminoguanidine and pentoxifylline in modulating endotoxin-induced cardiac stress. Cell Biochem. Funct. 29(8), 694–702 (2011).
   PubMed Web of Science ®Google Scholar
• Portakal O, Inal-Erden M. Effects of pentoxifylline and coenzyme Q10 in hepatic ischemia/reperfusion injury. Clin. Biochem. 32(6), 461–466 (1999).
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Lederman MM, Spritzler JG et al. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J. Infect. Dis. 171(6), 1628–1632 (1995).
   PubMed Web of Science ®Google Scholar
• Bansilal S, Castellano JM, Garrido E et al. Assessing the impact of medication adherence on long-term cardiovascular outcomes. J. Am. Coll. Cardiol. 68(8), 789–801 (2016).
   PubMed Web of Science ®Google Scholar
• Namdar H, Zohori R, Aslanabadi N, Entezari-Maleki T. Effect of pentoxifylline in ameliorating myocardial injury in patients with myocardial infarction undergoing thrombolytic therapy: a pilot randomized clinical trial. J. Clin. Pharmacol. 57(10), 1338–1344 (2017).
   PubMed Web of Science ®Google Scholar
• Husted S, Storey RF, Harrington RA, Emanuelsson H, Cannon CP. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin. Cardiol. 33(4), 206–212 (2010).
   PubMed Web of Science ®Google Scholar
• Ariotti S, Ortega-Paz L, Van Leeuwen M et al. Effects of ticagrelor, prasugrel, or clopidogrel on endothelial function and other vascular biomarkers: a randomized crossover study. JACC Cardiovasc. Interv. 11(16), 1576–1586 (2018).
   PubMed Web of Science ®Google Scholar